利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.014 秒)

    Pyrazinone derivatives
    2.
    发明授权
    Pyrazinone derivatives 失效
    吡嗪酮衍生物

    公开(公告)号：US07148224B2

    公开(公告)日：2006-12-12

    申请号：US11105534

    申请日：2005-04-14

    申请人： Takashi Hayama ,  Nobuhiko Kawanishi ,  Tooru Takaki

    发明人： Takashi Hayama ,  Nobuhiko Kawanishi ,  Tooru Takaki

    IPC分类号： A01N43/58 ,  A01N43/60 ,  A61K31/50 ,  A61K31/495 ,  C07D471/00

    CPC分类号： C07D213/75 ,  C07D277/48 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D487/04

    摘要： The present invention relates to a compound of the general formula (I): [Ar1 is aryl fused to the adjacent pyrazinone ring at the 5th and 6th positions, etc., X is CO, etc., Y is CH, etc., Z is CH, etc., V is CH, etc., Wn is —(CH2)n— (n is zero to four), R1, is H or optionally substituted lower alkyl, etc., R2 is H, etc., R3 and R4 are the same or different and are each H, etc., R5 and R6 are the same or different and are each H, hydroxy, etc.] or a pharmaceutically acceptable salt or ester thereof; a pharmaceutical composition, an inhibitor of Cdk4 and/or Cdk6 or an anti-cancer agent, containing the same as an active ingredient; and a process for preparing them.

    摘要翻译： 本发明涉及通式（I）的化合物：[Ar 1]在第5和6位与相邻的吡嗪酮环稠合的芳基等，X是CO等， Y是CH等，Z是CH等，V是CH等，W n是 - （CH 2）n

    Pyrazinone derivatives
    3.
    发明授权
    Pyrazinone derivatives 失效
    吡嗪酮衍生物

    公开(公告)号：US06914062B2

    公开(公告)日：2005-07-05

    申请号：US10312500

    申请日：2001-06-28

    申请人： Takashi Hayama ,  Nobuhiko Kawanishi ,  Tooru Takaki

    发明人： Takashi Hayama ,  Nobuhiko Kawanishi ,  Tooru Takaki

    IPC分类号： A61P35/00 ,  A61P43/00 ,  C07D213/75 ,  C07D277/48 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D487/04 ,  A01N43/58 ,  A01N43/60 ,  A61K31/495 ,  A61K31/50 ,  C07D475/00

    CPC分类号： C07D213/75 ,  C07D277/48 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D487/04

    摘要： The present invention relates to a compound of the general formula (I): [Ar1 is aryl fused to the adjacent pyrazinone ring at the 5th and 6th positions, etc., X is CO, etc., Y is CH, etc., Z is CH, etc., V is CH, etc., Wn is —(CH2)n— (n is zero to four), R1 is H or optionally substituted lower alkyl, etc., R2 is H, etc., R3 and R4 are the same or different and are each H, etc., R5 and R6 are the same or different and are each H, hydroxy, etc.] or a pharmaceutically acceptable salt or ester thereof; a pharmaceutical composition, an inhibitor of Cdk4 and/or Cdk6 or an anti-cancer agent, containing the same as an active ingredient; and a process for preparing them.

    摘要翻译： 本发明涉及通式（I）的化合物：[Ar 1]在第5和6位与相邻的吡嗪酮环稠合的芳基等，X是CO等， Y是CH等，Z是CH等，V是CH等，W n是 - （CH 2）n - （n为0至4），R 1为H或任选取代的低级烷基等，R 2为H等，R 3 R 3和R 4相同或不同，各自为H等，R 5和R 6相同或不同， 不同且各自为H，羟基等]或其药学上可接受的盐或酯; 药物组合物，Cdk4和/或Cdk6抑制剂或抗癌剂，其含有活性成分; 和一个准备它们的过程。